When will apixaban be generic?

I can help, but the answer depends on the country and the patent situation.

- In the United States: apixaban (Eliquis) is protected by multiple patents and data exclusivity. The main composition patent is generally expected to expire around 2026, with possible extensions from pediatric exclusivity (adds about 6 months) and other later-filed patents that could delay generic entry. The actual availability of a generic depends on patent litigation outcomes and any settlements with generic manufacturers. So, a generic US entry could be late 2020s if there are no blockers, but the exact date isn’t fixed until patents/liability issues are resolved.

- In other countries: patent expiry and market exclusivity vary by country and by whether the country recognizes different patent types (composition patents, method-of-use patents, regulatory exclusivities, etc.). So timing can be earlier or later than the US.

If you tell me your country (and whether you want the latest official timing), I can provide a more precise answer and point you to the official sources.

Useful sources to check now:
- US: FDA Orange Book for listed patents and expiries related to apixaban (Eliquis).
- EU/other regions: national patent information and regulatory exclusivity data from the respective medicines agencies.

Would you like me to look up the current status for a specific country? If yes, which country?